These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 33484864)

  • 21. Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia.
    Tang HJ; Wang JH; Lai CC
    Medicine (Baltimore); 2020 Jul; 99(29):e21223. PubMed ID: 32702892
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Omadacycline for Acute Bacterial Skin and Skin-Structure Infections.
    O'Riordan W; Green S; Overcash JS; Puljiz I; Metallidis S; Gardovskis J; Garrity-Ryan L; Das AF; Tzanis E; Eckburg PB; Manley A; Villano SA; Steenbergen JN; Loh E
    N Engl J Med; 2019 Feb; 380(6):528-538. PubMed ID: 30726689
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of omadacycline in the treatment of
    Wang Y; Yi SM; Huang SM; Xu WX; Wei YW; Qu Q; Qu J
    Front Cell Infect Microbiol; 2024; 14():1380312. PubMed ID: 38836055
    [No Abstract]   [Full Text] [Related]  

  • 24. Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study of the Effects of Omadacycline on QT/QTc Intervals in Healthy Subjects.
    Darpo B; Xue H; Tanaka SK; Tzanis E
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31405867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial.
    Alexander E; Goldberg L; Das AF; Moran GJ; Sandrock C; Gasink LB; Spera P; Sweeney C; Paukner S; Wicha WW; Gelone SP; Schranz J
    JAMA; 2019 Nov; 322(17):1661-1671. PubMed ID: 31560372
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Omadacycline in Skin Infections and Pneumonia: A Review of the Evidence.
    Vacalis S; Brunton S; Gindi J
    J Fam Pract; 2022 Jun; 71(5 Suppl):S10-S21. PubMed ID: 35776862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The pharmacokinetic evaluation of omadacycline (Oral Only Dosing Regimen) for the treatment of Community-Acquired Bacterial Pneumonia (CABP).
    Cilloniz C; Torres A
    Expert Opin Drug Metab Toxicol; 2023 Sep; 19(9):569-576. PubMed ID: 37728376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An Integrated Safety Summary of Omadacycline, a Novel Aminomethylcycline Antibiotic.
    Opal S; File TM; van der Poll T; Tzanis E; Chitra S; McGovern PC
    Clin Infect Dis; 2019 Aug; 69(Suppl 1):S40-S47. PubMed ID: 31367740
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Omadacycline for Acute Bacterial Skin and Skin Structure Infections.
    Abrahamian FM; Sakoulas G; Tzanis E; Manley A; Steenbergen J; Das AF; Eckburg PB; McGovern PC
    Clin Infect Dis; 2019 Aug; 69(Suppl 1):S23-S32. PubMed ID: 31367742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Omadacycline: First Global Approval.
    Markham A; Keam SJ
    Drugs; 2018 Dec; 78(18):1931-1937. PubMed ID: 30471003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Omadacycline Oral Dosing and Pharmacokinetics in Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infection.
    Leviton IM; Amodio-Groton M
    Clin Drug Investig; 2022 Mar; 42(3):193-197. PubMed ID: 35192150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Review of Omadacycline for Potential Utility in the Military Health System for the Treatment of Wound Infections.
    Zurawski DV; Serio AW; Black C; Pybus B; Akers KS; Deck DH; Johnson S; Chattagul S; Noble SM; Raynor M; Lanteri CA
    Mil Med; 2024 May; 189(5-6):e1353-e1361. PubMed ID: 37963013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
    Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
    Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics, Safety, and Clinical Outcomes of Omadacycline in Women with Cystitis: Results from a Phase 1b Study.
    Overcash JS; Bhiwandi P; Garrity-Ryan L; Steenbergen J; Bai S; Chitra S; Manley A; Tzanis E
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia.
    Zhanel GG; Hartel E; Adam H; Zelenitsky S; Zhanel MA; Golden A; Schweizer F; Gorityala B; Lagacé-Wiens PR; Walkty AJ; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2016 Dec; 76(18):1737-1757. PubMed ID: 27909995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Omadacycline in treating community-based infections: a review and expert perspective.
    Sakoulas G; Nowak M; Geriak M
    Expert Rev Anti Infect Ther; 2023 Mar; 21(3):255-265. PubMed ID: 36718489
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group.
    Patel T; Pearl J; Williams J; Haverstock D; Church D
    Respir Med; 2000 Feb; 94(2):97-105. PubMed ID: 10714413
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Dubois J; Dubois M; Martel JF
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Omadacycline: A Modernized Tetracycline.
    Gallagher JC
    Clin Infect Dis; 2019 Aug; 69(Suppl 1):S1-S5. PubMed ID: 31367739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Omadacycline: a therapeutic review of use in community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
    Chopra T; Sandhu A; Theriault N; Meehan J; Tillotson G
    Future Microbiol; 2020 Sep; 15():1319-1333. PubMed ID: 32959689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.